Latest news
FDA rebuffs ITM's radiotherapeutic for neuroendocrine tumours - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 22:07:20 GMTAbCellera's hot flash antibody shows promise for once-monthly dosing - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 22:07:20 GMTJazz to buy Actio for up to $1.3B, gaining epilepsy asset - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 19:37:19 GMTMoonLake touts Phase III PsA data, but investors may have wanted more - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 18:17:18 GMTSilence posts mid-stage polycythemia vera win, preps for Phase III - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 18:02:18 GMTPhysician Views Preview: Orzeyful arrives — Will Takeda's drug redefine narcolepsy treatment? - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 16:47:18 GMTVertex's would-be rival Sionna scraps cystic fibrosis drug add-on after trial flop - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 16:12:18 GMTSobi, Innate sign $580M pact to propel lymphoma drug through Phase III - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 15:27:17 GMT